

LIVIA GROUP SELLS CAPUA BIOSERVICES TO OLON S.p.A.

Munich, 25.01.2019 - **LIVIA Corporate Development SE** announces the sale of its subsidiary **Capua BioServices S.p.A.** to **Olon S.p.A.**, a world leading Active Pharmaceutical Ingredients contract development and manufacturing organization and generics supplier located in Rondano, Italy.

Capua BioServices is one of the world's largest independent microbial fermentation-based manufacturing facilities. The company offers solutions for proteins, specialty small molecules and microorganisms focused on applications in the food, feed, pharma, agrochemical and fine chemical industry to customers in more than 60 countries.

Since the acquisition in 2015, LIVIA was able to develop the then mainly captive toll-manufacturer for the Patheon group (today part of Thermo Fisher Scientific Inc.) into a global provider of high-quality services in the field of custom microbial process development and manufacturing. With strategic investments in infrastructure and production facilities and by growing the highly skilled workforce from 165 to 230 employees, the company was able to grow its customer base, utilize its production capacities and improve overall profitability. Customer Portfolio include global Pharma and Food companies that have chosen Capua for its outstanding expertise and top quality approach. As a result, the formerly loss-making company has since almost doubled its sales level while improving EBITDA margin to more than 16%, an impressive figure above market standard.

"Our investment in Capua BioServices has been a great success story for all the stakeholders in the business. The sale of Capua to a strategic buyer is the final piece in our strategy of fully utilize Capua's potential", comments **Prof. Dr. Dr. Peter Löw, founder and owner of LIVIA GROUP**. "Like Capua, Olon is pursuing an ambitious growth strategy and is in a perfect position to support the company in its future development."

"In Capua BioServices we have seen a high standing player which will add value to our activities. In a dynamic and very competitive field such as the pharma-chemicals and CDMO industries, it is crucial to have extensive, transversal and specialised competences" **Paolo Tubertini, CEO of Olon** comments the Transaction.

It is customary not to disclose the financial details of the transaction.

estate, emerging markets, and fine arts & antiques. More than 250 executed transactions made LIVIA's management a preferred and trusted partner of international corporations and financial institutions.

LIVIA Corporate Development is specialized in acquiring European corporate spin-offs / carve-outs as well as mid-sized companies with revenues between EUR 20m and EUR 2bn. The focus is on business transformations and acquisitions of underperforming companies with operational improvement potential as well as add-on acquisitions for existing platform investments to realize synergies.

www.livia-group.com

Olon S.p.A. is an Italian manufacturer of APIs, with Headquarters and several manufacturing facilities located in Italy and originates from the merger of the previous Solmag and Antibiotics. With more than a century experience in fermentation Olon is one of the most important players in the production of High Potency Drugs, as well as cytotoxic substances.